Investigational drug · Phase 2
MK-2214
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Early Alzheimer's Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "MK-2214"
First trial start
2025
Jul 16, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MK-2214", any sponsor or status.
Conditions studied
As listed on its trial records.
- Early Alzheimer's Disease
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "MK-2214" as an intervention, largest first.
- A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07033494 · 340 participants (planned) · Start Jul 16, 2025 · Primary completion Apr 30, 2029
Drug: MK-2214; Placebo · For: Early Alzheimer's Disease
Sites: Irvine, California; Long Beach, California; Los Angeles, California · 80 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05466422 · 34 participants · Start Sep 20, 2022 · Primary completion Jul 3, 2025
Drug: MK-2214; Placebo · For: Alzheimer Disease
Sites: Glendale, California; Los Alamitos, California; Orange, California · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies.
Panza F, Dibello V, Sardone R, et al. · Expert Opin Investig Drugs 2023
Also in development for Early Alzheimer's Disease
- SemagludtidePhase 32 trials
Lumos Pharma · Obesity & Overweight, Early Alzheimer's Disease
- CT1812Study Drug ActivePhase 22 trials
Cognition Therapeutics · Early Alzheimer's Disease, Dementia With Lewy Bodies
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.